Upgrade to SI Premium - Free Trial

Abivax (ABVX)

90.23 -3.26 (3.49%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/14/26)

Latest Headlines

Piper Sandler on Abivax (ABVX): 'Obefazimod's Differentiated Profile Reinforced by UEGW Data' October 21, 2026 8:45 AM - StreetInsider Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 September 30, 2026 4:05 PM - Globe NewsWire Abivax (ABVX) PT Lowered to $151 at Truist Securities September 22, 2026 7:15 AM - StreetInsider Form F-6EF Abivax S.A. Filed by: Citibank,N.A./ADR September 21, 2026 4:21 PM - SEC Filing Form 6-K Abivax S.A. For: Jun 30 September 21, 2026 4:13 PM - SEC Filing Abivax Presents Business Updates and First Half 2026 Financial Results  September 21, 2026 4:05 PM - Globe NewsWire This biotech stock has 'multiblockbuster IBD opportunity': analyst September 10, 2026 5:00 PM - StreetInsider Goldman Sachs Starts Abivax (ABVX) at Buy, 'screens well as a potential M&A target' September 9, 2026 4:41 PM - StreetInsider Form SCHEDULE 13G/A Abivax S.A. Filed by: TCG Crossover GP I, LLC August 14, 2026 4:31 PM - SEC Filing Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC August 13, 2026 10:55 AM - SEC Filing Abivax completes pre-NDA meeting with FDA for ulcerative colitis drug July 30, 2026 4:07 PM - StreetInsider Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod July 30, 2026 4:05 PM - Globe NewsWire Abivax (ABVX) PT Raised to $180 at Morgan Stanley July 24, 2026 9:38 AM - StreetInsider Full Article List